Fig. 1: Murine EML4-ALK cell lines exhibit equal in vitro sensitivity to TKIs.
From: Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
a EA1, EA2, and EA3 cells were seeded at 100 cells/well in 96-well plates and cultured in growth medium containing the indicated concentrations of the TKIs, alectinib or lorlatinib. After 7 days of incubation, cell number was determined using the CyQUANT assay (see “Methods”). Data (mean and SEM of triplicate determinations) are presented as percent of wells treated with medium containing 0.1% DMSO. The IC50 values for alectinib (7.6, 12.4, and 6.7 nM for EA1, EA2, and EA3, respectively) and lorlatinib (1.7, 3.8, and 1.7 nM for EA1, EA2, and EA3, respectively) were calculated with Prism 9. b RNAseq data from the murine EML4-ALK cell lines treated with and without alectinib (see “Methods”) were queried for known MAPK target genes, ETV4, ETV5, FOSL1, and DUSP6. The mRNA expression values (CPMs) were converted to Z-scores and presented as a heatmap.
